TABLE 1.
Clinical and Pathological Characteristics of 137 Patients According to their Relapse Status
| Characteristic | All cases | No relapse | Relapse | p |
|---|---|---|---|---|
| No. of patients | 137 | 97 | 40 | |
| Age at diagnosis, years | .929a | |||
| Mean (SD) | 65.3 (8.9) | 65.3 (9.5) | 65.2 (7.4) | |
| Median (min‐max) | 64 (43–89) | 64 (43–89) | 65 (53–81) | |
| BMI, kg/m2 b | .654c | |||
| Mean (SD) | 29.3 (6.9) | 29.2 (7.2) | 29.4 (5.9) | |
| Median (min‐max) | 28.3 (18.2–51.4) | 28.3 (18.2–51.4) | 28.7 (20.4–41.4) | |
| Missing | 24 | 14 | 10 | |
| FIGO stage (2009) | .943 | |||
| IA | 61 (44.5) | 43 (44.3) | 18 (45.0) | |
| IB | 76 (55.5) | 54 (55.7) | 22 (55.0) | |
| Tumor grade | .574 | |||
| 1 or 2 | 74 (54.1) | 54 (55.7) | 20 (50.0) | |
| 3 | 63 (46) | 43 (44.3) | 20 (50.0) | |
| Histology | .811 | |||
| Endometrioid | 121 (88.3) | 85 (87.6) | 36 (90.0) | |
| Not endometrioid | 16 (11.7) | 12 (12.4) | 4 (10.0) | |
| LVSI | .977 | |||
| Negative | 88 (64.2) | 62 (63.9) | 26 (65.0) | |
| Focal | 27 (19.7) | 19 (19.6) | 8 (20.0) | |
| Substantial | 22 (16.1) | 16 (16.5) | 6 (15.0) | |
| Myometrial invasion | .660 | |||
| None | 7 (5.1) | 6 (6.2) | 1 (2.5) | |
| <50% | 55 (40.1) | 38 (39.2) | 17 (42.5) | |
| ≥50% | 75 (54.7) | 53 (54.6) | 22 (55.0) | |
| Lymph node assessment | ||||
| Not surgically tested | 62 (45.3) | 43 (44.3) | 19 (47.5) | .735 |
| Sentinel lymph node | 15 (10.9) | 11 (11.3) | 4 (10.0) | .819 |
| Lymphadenectomyd | 65 (47.4) | 46 (47.4) | 19 (47.5) | .993 |
| Only pelvic lymphadenectomy | 59/65 (90.8) | 42/46 (91.3) | 17/19 (89.5) | .817 |
| Pelvic and aortic lymphadenectomy | 6/65 (9.2) | 4/46 (8.7) | 2/19 (10.5) | |
| 2020 ESGO/ESTRO/ESP risk group with unknown molecular classification | .635 | |||
| Low | 38 (27.7) | 29 (29.9) | 9 (22.5) | |
| Intermediate | 46 (33.6) | 30 (30.9) | 16 (40.0) | |
| High‐intermediate | 39 (28.5) | 27 (27.8) | 12 (30.0) | |
| High | 14 (10.2) | 11 (11.3) | 3 (7.5) | |
| 2020 ESGO/ESTRO/ESP risk group with known molecular classification | .136 | |||
| Low | 35/127 (27.6) | 29/93 (31.2) | 6/34 (17.6) | |
| Intermediate | 36/127 (28.3) | 24/93 (25.8) | 12/34 (35.3) | |
| High‐intermediate | 31/127 (24.4) | 25/93 (26.9) | 6/34 (17.6) | |
| High | 25/127 (19.7) | 15/93 (16.1) | 10/34 (29.4) | |
| Postsurgical treatment | .240 | |||
| No | 48 (35.0) | 31 (32.0) | 17 (42.5) | |
| Yes | 89 (65.0) | 66 (68.0) | 23 (57.5) | |
| Follow‐up | ||||
| Relapse | 40 (29.2) | 0 (0) | 40 (100) | — |
| Type of relapsee | ||||
| Single site | 20/34 (58.8) | — | 20/34 (58.8) | |
| Multiple sites | 14/34 (41.2) | — | 14/34 (41.2) | |
| Sitee | ||||
| Centropelvic | 20/34 (58.8) | — | 20/34 (58.8) | |
| Lymphatic | 10/34 (29.4) | — | 10/34 (29.4) | |
| Hematogenous | 12/34 (35.3) | — | 12/34 (35.3) | |
| Peritoneal | 1/34 (2.9) | — | 1/34 (2.9) | |
| Port site | 6/34 (17.6) | — | 6/34 (17.6) | |
| Death | 34 (24.8) | 10 (10.3) | 24 (60.0) | <.0001 |
Note: Results are presented as n (%) except where indicated. p values have been calculated with the Pearson χ2 test except where indicated.
Abbreviations: BMI, body mass index; ESGO, European Society of Gynaecological Oncology; ESP, European Society of Pathology; ESTRO, European Society for Radiotherapy and Oncology; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; SD, standard deviation.
Calculated with the Student t‐test.
Information was available for 113 of 137 patients.
Calculated with the Mann–Whitney test.
Five patients underwent both a sentinel lymph node assessment and lymphadenectomy.
Information was available for 34 of 40 patients who experienced relapse.